Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02124148 · ClinicalTrials.gov registry record · Phase 1

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

A Phase 1 study of Breast Cancer and Colorectal Neoplasms, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
167
Enrollment target
5
Study locations

NCT02124148: Completed Phase 1 study of Breast Cancer and Colorectal Neoplasms, sponsored by Eli Lilly and Company.

NCT02124148 is a Phase 1 study of Breast Cancer and Colorectal Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 167 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02124148, a Phase 1 study of Breast Cancer and Colorectal Neoplasms, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
167 participants
Enrollment target
5
Study locations

Study Summary

The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.

Interventions

  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG G-CSF
  • DRUG Cetuximab
  • DRUG Prexasertib

Study Locations (5)

Tennessee

  • Sarah Cannon Research Institute SCRI - Nashville
  • Tennessee Oncology PLLC - Nashville

Florida

  • Florida Cancer Specialists - Sarasota

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2014-06-18
Est. Completion 2020-02-13
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT02124148 record still lists

NCT02124148 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT02124148 lists 5 locations in 4 states (Tennessee, Florida, Oklahoma).

Frequently Asked Questions

What is clinical trial NCT02124148 about?

NCT02124148 is a clinical study titled "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer". The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple part...

What is the current status of trial NCT02124148?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 167 participants. The study started on 2014-06-18. Estimated completion is 2020-02-13.

What conditions does trial NCT02124148 study?

This clinical trial studies the following conditions: Breast Cancer, Colorectal Neoplasms, Neoplasm Metastasis.

What interventions are being tested in trial NCT02124148?

The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), G-CSF (DRUG), Cetuximab (DRUG), Prexasertib (DRUG).

Who is sponsoring clinical trial NCT02124148?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02124148 being conducted?

This trial has 5 study locations across Florida, Oklahoma, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02124148's enrollment target sits among peer trials

167 425th of 1224 higher than 800 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04248283 · 167 participants · NA

    Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

  • NCT04552509 · 167 participants · NA

    TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

  • NCT05516277 · 167 participants · NA

    Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02124148, the US trial registry maintained by the National Library of Medicine. NCT02124148 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.